Travere Therapeutics (TVTX) reported $81.73 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 97.6%. EPS of -$0.47 for the same period compares to -$1.76 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $79.35 million, representing a surprise of +3.00%. The company delivered an EPS surprise of +14.55%, with the consensus EPS estimate being -$0.55.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.55%. A quarter ago, it was expected that this drug developer would post a loss of $0.58 per share when it actually produced a loss of $0.73, delivering a surprise of -25.86%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name o ...

Travere Therapeutics (TVTX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to the Traveer Therapeutics First Quarter twenty twenty five Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Victoria Prescott, Manager of Investor Relations. Please go ahead, Victoria. Speaker1 Thank you, Chloe. Good afternoon, and welcome to Traveo Therapeutics first quarter twenty twenty five financial results and ...

Core Viewpoint - Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI, aiming for it to be the first FDA-approved treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney condition [1][2] Company Overview - Travere Therapeutics is focused on developing therapies for rare diseases, emphasizing the urgent need for effective treatment options for conditions like FSGS [2][8] - FILSPARI is currently approved for slowing kidney function decline in adults with IgA nephropathy and is a non-immunosuppressive oral medication [2][9] Clinical Studies - The sNDA submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, which are among the largest interventional studies in FSGS [1][6] - The DUPLEX Study achieved its interim endpoint with statistical significance at 36 weeks, showing significant proteinuria reduction and a lower rate of end-stage kidney disease compared to the active control [6][7] - The DUET Study demonstrated a greater than two-fold reduction in proteinuria compared to irbesartan, with a consistent safety profile across trials [7] Regulatory Process - The FDA has 60 days to determine whether to accept the sNDA for review, with an expected notice in the second quarter of 2025 [3] - The FDA has indicated that REMS monitoring for embryo-fetal toxicity is no longer necessary, and the company plans to submit a modification to the REMS [4] Disease Context - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S., characterized by progressive scarring of the kidney and leading to kidney failure [5] - There are currently no FDA-approved pharmacologic therapies for FSGS, highlighting the significance of FILSPARI's potential approval [5]

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices) TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) For the Fiscal Year Ended December 31, 2024 Delaware 27-4842691 ...

Travere Therapeutics (TVTX) reported $74.79 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 66%. EPS of -$0.73 for the same period compares to -$1.16 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $73.44 million, representing a surprise of +1.84%. The company delivered an EPS surprise of -25.86%, with the consensus EPS estimate being -$0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compar ...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.86%. A quarter ago, it was expected that this drug developer would post a loss of $0.70 per share when it actually produced a loss of $0.70, delivering no surprise.Over the last four quarters, the company has not ...

EXHIBIT 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Provides Corporate Update and 2025 Outlook Received 693 new patient start forms for FILSPARI (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter ® sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025 Company ...